Literature DB >> 20346226

CXCR7 in tumorigenesis and progression.

Kai-Lin Hou1, Ming-Gang Hao, Juan-Jie Bo, Jian-Hua Wang.   

Abstract

Chemokines, a family of small cytokines, were initially characterized as proinflammatory chemoattractant cytokines that regulated cell trafficking and adhesion. Today, attention focuses on chemokines because evidence shows that they play a critical role in tumor initiation, promotion, and progression. CXCR7, a seven-transmembrane G-protein-coupled CXC chemokine receptor, has recently been identified as binding with high affinity to chemokines CXCL11 (I-TAC) and CXCL12 (SDF-1). In this review, we highlight the current knowledge about the role of CXCR7 in the biologic processes of cancer, including cancer growth, survival, adhesion, invasion, metastasis, angiogenesis, and progression. The use of peptides, small molecules, antibodies, or small interfering RNA to target CXCR7 shows promise as new potential avenues for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346226     DOI: 10.5732/cjc.009.10404

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


  9 in total

Review 1.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

2.  C-X-C motif receptor 7 in gastrointestinal cancer.

Authors:  Hwan-Jung Yun; Hyewon Ryu; Yoon Seok Choi; Ik-Chan Song; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

3.  The APC tumor suppressor is required for epithelial cell polarization and three-dimensional morphogenesis.

Authors:  Alyssa C Lesko; Kathleen H Goss; Frank F Yang; Adam Schwertner; Imge Hulur; Kenan Onel; Jenifer R Prosperi
Journal:  Biochim Biophys Acta       Date:  2015-01-08

4.  CXCL12 enhances human neural progenitor cell survival through a CXCR7- and CXCR4-mediated endocytotic signaling pathway.

Authors:  Bing Zhu; Dongsheng Xu; Xiaobei Deng; Qiang Chen; Yunlong Huang; Hui Peng; Yuju Li; Beibei Jia; Wallace B Thoreson; Wenjun Ding; Jianqing Ding; Lixia Zhao; Yi Wang; Kristin Leland Wavrin; Shumin Duan; Jialin Zheng
Journal:  Stem Cells       Date:  2012-11       Impact factor: 6.277

Review 5.  Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.

Authors:  Ismael Ghanem; Maria E Riveiro; Valerie Paradis; Sandrine Faivre; Paula M Vázquez de Parga; Eric Raymond
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

6.  CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver.

Authors:  E Guillemot; B Karimdjee-Soilihi; E Pradelli; M Benchetrit; E Goguet-Surmenian; M-A Millet; F Larbret; J-F Michiels; D Birnbaum; P Alemanno; H Schmid-Antomarchi; A Schmid-Alliana
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

7.  CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not.

Authors:  Maria Neve Polimeno; Caterina Ierano; Crescenzo D'Alterio; Nunzia Simona Losito; Maria Napolitano; Luigi Portella; Giosuè Scognamiglio; Fabiana Tatangelo; Anna Maria Trotta; Steven Curley; Susan Costantini; Raffaele Liuzzi; Francesco Izzo; Stefania Scala
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

8.  High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.

Authors:  Linhui Wang; Wei Chen; Li Gao; Qing Yang; Bing Liu; Zhenjie Wu; Yang Wang; Yinghao Sun
Journal:  World J Surg Oncol       Date:  2012-10-07       Impact factor: 2.754

Review 9.  Rationale for the design of an oncology trial using a generic targeted therapy multi‑drug regimen for NSCLC patients without treatment options (Review).

Authors:  Stefan Langhammer
Journal:  Oncol Rep       Date:  2013-07-22       Impact factor: 3.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.